Design, synthesis and pharmacological analysis of 5-[4′-(substituted-methyl)[1,1′-biphenyl]-2-yl]-1H-tetrazoles
作者:Atulkumar Kamble、Ravindra Kamble、Suneel Dodamani、Sunil Jalalpure、Vijaykumar Rasal、Mahadev Kumbar、Shrinivas Joshi、Sheshagiri Dixit
DOI:10.1007/s12272-017-0887-0
日期:2017.4
In the present paper 5-[4′-(4-[(4-aryloxy)methyl]-1H-1,2,3-triazol-1-yl}methyl)[1,1′-biphenyl]-2-yl]-1H-tetrazoles (5a–g) and [2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl-substituted-1-carbodithioates (11h–q) have been designed and synthesized. These compounds were subjected to docking (against AT1 receptor protein enzyme in complex with Lisinopril), in vitro angiotensin converting enzyme inhibition
在本文中 5-[4'-(4-[(4-芳氧基)甲基]-1H-1,2,3-三唑-1-基}甲基)[1,1'-联苯]-2-基]-1H-四唑 (5a-g) 和 [2'-(1H-四唑-5-基)[1,1'-联苯]-4-基]甲基-取代的-1-碳二硫代酸酯 (11h-q)已经设计和合成。这些化合物经过对接(针对与赖诺普利复合的 AT1 受体蛋白酶)、体外血管紧张素转化酶抑制、抗增殖、抗炎筛选(通过卵白蛋白变性抑制和红细胞膜稳定试验),最后抗- 真菌活性分析。一些化合物已显示出显着的药理特性。